Search clinical trials for: MT10109L

Total 9 results

Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Medy-Tox

Completed

MT10109L in the Treatment of Lateral Canthal Lines

Lateral Canthal Lines

United States, Russian Federation, United Kingdom
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines

Glabellar Lines

United States, Belgium, Russian Federation
Medy-Tox

Completed

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada, United Kingdom
Medy-Tox

Completed

Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia

Cervical Dystonia

Australia
Medy-Tox

Completed

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Glabellar Frown Lines

Australia
Medy-Tox

Completed

Pharmacodynamic and Safety of MT10107(Botulinum Type A Neurotoxin) in Comparison to BOTOX®

Healthy Volunteers

Korea, Republic of
Medy-Tox

Completed

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

Glabellar Frown Lines

3

Subscribe